Following these first successes, INX-3280, a 15-mer phosphorothioate oligonucleotide against the c-myc oncogene, was in Phase I and II clinical trials for the treatment of lymphoma and solid tumors more than a decade ago, but was discontinued in 2002 by Inex. This evidence concerns the gene MYC and lymphoma.